Pressure Injuries Due to Personal Protective Equipment in COVID-19 Critical Care Units

Background Caring for patients with COVID-19 requires wearing a full set of personal protective equipment (PPE) to avoid contamination. Personal discomfort has been associated with use of PPE, and anecdotal reports describe pressure injuries related to wearing PPE. Objectives To investigate the occurrence of device-related pressure injuries due to wearing PPE among Italian nurses caring for patients with COVID-19 in critical care settings. Methods This descriptive study used an online survey investigating both the demographic characteristics of respondents and complications related to wearing PPE, including the development of pressure injuries. Results A total of 266 nurses throughout Italy completed the survey; 32% of respondents were men. Nurses’ median age was 36 years (range 22-59 years), and the median time spent working in their current clinical setting (an intensive care or high-dependency unit) was 3 years (range 0-32 years). Personal protective equipment was worn for a median duration of 5 hours (range 2-12 hours). While wearing PPE, 92.8% of nurses experienced pain and 77.1% developed device-related pressure injuries, mainly on the nose and forehead. Pain was more frequent among nurses with such injuries. Transparent dressings, emollient cream, and no dressing were associated with development of device-related pressure injury. Conclusions Pressure injuries related to PPE represent an important adverse effect for nurses caring for patients with COVID-19. This topic deserves study to determine adequate solutions for preventing and treating such injuries and their potential influence on nurses’ work tolerance.

Compounded Topical Amitriptyline for Neuropathic Pain: In Vitro Release from Compounding Bases and Potential Correlation with Clinical Efficacy

ABSTRACTBackground: Topical amitriptyline has been described as having mixed clinical efficacy for neuropathic pain. A few case reports using higher concentrations of this compound found clinical benefit, but many of these studies did not describe the components used in formulating the amitriptyline preparations.Objective:To generate reproducible clinical measures of the characteristics of amitriptyline diffusion from selected compounding bases, to support a scientific approach to base selection when compounding this drug for neuropathic pain.Methods: Amitriptyline hydrochloride (1%, 5%, and 10%) was compounded with 3 proprietary compounding bases: Lipoderm base, Emollient Cream, and Mediflo 30 pluronic lecithin organogel (PLO) gel. In vitro release of the drug from each base and subsequent permeation across artificial human skin were investigated with the Franz diffusion system. Amitriptyline release mechanisms were determined with kinetic models. How quickly and to what extent the drug leaves each base to diffuse through the skin were characterized by determining steady-state flux, cumulative permeation, and lag times.Results: Release of amitriptyline was significantly higher from the Mediflo PLO gel than from the Lipoderm base or Emollient Cream (p < 0.05). Mean cumulative drug release after 24 h, from the 10% formulation, was 23.9% (standard deviation [SD] 4.1%) for Lipoderm base, 41.8% (SD 3.1%) for Emollient Cream, and 53.2% (SD 7.7%) for Mediflo PLO gel. A high percentage of amitriptyline was retained in all 3 bases. Although amitriptyline release was highest with Mediflo PLO gel, this base resulted in significantly lower cumulative permeation relative to Lipoderm base and Emollient Cream (p < 0.05). There was a strong overall correlation between amitriptyline concentration, lag time, and flux. Higher concentrations were associated with significantly lower lag times and increased flux. The highest lag time and flux were observed for Mediflo PLO gel.Conclusion: These data indicate that the therapeutic effectiveness of compounded amitriptyline for neuropathic pain depends on its diffusion out of the compounding bases and penetration through the skin. RÉSUMÉContexte : L’efficacité clinique de l’amitriptyline topique contre les douleurs neuropathiques a été décrite comme étant variable. Quelques rapports utilisant des concentrations plus élevées de cette base indiquent des avantages cliniques, mais bon nombre d’entre eux ne décrivent pas les composants des préparations d’amitriptyline.Objectif : Établir des mesures cliniques reproductibles des caractéristiques de la diffusion de l’amitriptyline selon une approche scientifique de la sélection des bases pour la préparation de ce médicament contre les douleurs neuropathiques.Méthodes : Le chlorohydrate d’amitriptyline (1 %, 5 % et 10 %) a été mélangé à trois bases de préparations magistrales brevetées : la base Lipoderm, la crème émolliente et le gel Mediflo PLO 30. La liberation in vitro du médicament de chaque base et la perméation qui s’en est suivie dans la peau humaine artificielle ont été étudiées à l’aide du système de diffusion Franz. La définition des mécanismes de libération de l’amitriptyline repose sur des modèles cinétiques. La rapidité et la durée de libération du médicament de chaque base pour se diffuser dans la peau ont été caractérisées par la détermination du flux constant, de la perméation cumulée et des temps de latence.Résultats : La libération de l’amitriptyline était sensiblement plus élevée quand le produit était mélangé au gel Mediflo PLO plutôt qu’à la base Lipoderm ou à la crème émolliente (p < 0,05). La libération cumulée du médicament, formule 10 %, après 24 h était de 23,9 % (écart type [É.T.] ± 4,1 %) avec la base Lipoderm; 41,8 % (É.T. ± 3,1 %) avec la crème émolliente et 53,2 % (É.T. ± 7,7 %) avec le gel Mediflo PLO. Les trois bases retenaient un pourcentage élevé d’amitriptyline. Bien que la libération d’amitriptyline était plus élevée en présence du gel Mediflo PLO, la perméation cumulée de cette base par rapport à celle de la base Lipoderm et de la crème émolliente était sensiblement moins élevée (p < 0,05). L’observation a révélé une forte corrélation générale entre la concentration d’amitriptyline, le temps de latence et le flux. Les concentrations plus élevées étaient associées à des temps de latence sensiblement moins élevés. C’est le gel Mediflo PLO qui a démontré une supériorité du temps de latence et du flux.

Topical corticosteroids induced hyper-pigmentation: a case report

<p>Hyper-pigmentation is a common skin condition in which increased melanin production results in darker patches of skin. Although hyper-pigmentation is harmless but still mostly people wish to get rid of them because of increasing craze of beautification in India. Topical corticosteroids (TC) application showed quick amelioration of post-inflammatory hyper-pigmentation patches. Prolonged and unsupervised use of TC leads to skin atrophy and reappearance of hyper-pigmentation patches. We present two cases of hyper-pigmentation induced by TC misuse. In case-1, a 20 year old female came to OPD with a complaint of hyper-pigmentation and itch sensation along with drug history of Betnovate cream for the last 2 years for acne treatment. On examination, she showed signs of hyper-pigmentation on cheeks. She was counselled to stop the further use of Betnovate cream and prescribed demelanizing agents along with sunscreen and emollients. The patches improved significantly with above management within 15 days. In case-2, a 33 year old female came to OPD with complaints of redness over whole face, increased facial hair growth and burning sensation along with drug history of using Betnovate cream for 2 years. On examination she showed signs of hyper-pigmentation and redness on cheeks, bruise and tearing of skin and increased facial hair growth. She was counselled to stop the further use of Betnovate cream. She was prescribed retinoic acid cream, sunscreen agents, anti-allergic tablets and emollient cream. The patches improved significantly with above management within 15 days.</p><p class="abstract"> </p>